Gilead’s Price Reduction Strategy: A Serious Move, But Not A Long-Term Model For US
Executive Summary
“Authorized generics” for Gilead's leading hepatitis C brands stands out from prior, largely symbolic responses to the lower list prices. This is not a political move, but a business one. It is also the clearest demonstration yet of why pricing reforms are necessary if lower list prices are the policy goal.